North Haven, Connecticut Clinical Trials

A listing of North Haven, Connecticut clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 54 clinical trials
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

ly573144
treatment regimen
lasmiditan
migraine
preventive medication
Yale New Haven Children's Hospital
 (6.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +162 other locations
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.

pleural effusions
carcinoma
neuropathy
major surgery
x rays
Smilow Cancer Hospital at Yale New Haven
 (6.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

bone marrow infiltration
pleural effusions
radiopharmaceutical therapy
pegfilgrastim
nervous system disorders
Yale University
 (6.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +82 other locations
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

solid tumour
solid tumor
kras g12c mutation
kras
ki-ras
Yale Cancer Center
 (6.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +7 other locations
Peer-led Social Media Intervention to Prevent HIV Among Young Men Who Have Sex With Men (YMSM)

The aim of this study is to examine the effect of social media intervention on the use of pre-exposure prophylaxis (PrEP) by young men who have sex with men (YMSM) in the greater New Haven area.

pre exposure prophylaxis
pre-exposure prophylaxis (prep)
pre-exposure prophylaxis
APNH: A Place to Nourish your Health (APNH)
 (6.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

antiandrogens
measurable disease
testosterone
cancer
taxane
Yale School of Medicine
 (6.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +21 other locations
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of …

resting tremor
genetic testing
tremor
datscan
modafinil
Institute For Neurodegenerative Disorders
 (6.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +45 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

imiglucerase
eliglustat
gaucher disease
deficiency
Investigational Site Number 840047
 (6.4 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +208 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840047
 (6.4 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +124 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

myozyme
gaa gene
replacement therapy
glycogen storage disease type ii
deficiency
Investigational Site Number 840047
 (6.4 away) Contact site
  • 0 views
  • 22 Dec, 2020
  • +168 other locations